BY MARKETWIRE
-
ChemoMetec posts strong start to the new financial year
The enhanced income is likewise mirrored in running earnings.
-
Novo Nordisk CEO challenges Pfizer on Metsera: “Put your hand in your pocket and bid higher”
On Thursday afternoon, the Financial Times reported that Novo Nordisk had once again raised its bid for Metsera.
-
Johnson & Johnson gets US approval for Genmab cancer drug
On Thursday night, the FDA accepted Darzalex for the therapy of h igh-risk smouldering several myeloma (SMM).
-
Novo Nordisk expects slight sales hit from Trump deal in 2026
The brand-new arrangement is anticipated to be applied in 2026.
-
Olympus cuts 2,000 jobs
An unsatisfactory operating result suggests Japanese endoscope vendor Olympus will certainly conserve JPY 24bn via discharges throughout the business.
-
Gubra maintains precise expectations: The search for new partnerships continues
Profits in the CRO company is anticipated to continue to be 5-10% less than in 2024, contrasted to formerly being somewhat less than in 2024.
-
Johnson & Johnson gets US approval for Genmab cancer drug
On Thursday evening, the FDA approved Darzalex for the treatment of high-risk smouldering multiple myeloma (SMM).
-
Novo Nordisk reopens talks with Hims & Hers over Wegovy sales after ditched partnership
Both events became part of a collaboration in April 2025, however it was ended in June complying with intense complaints from Novo Nordisk.
-
US healthcare giant buys controversial Kenvue
Kimberly-Clark gets Kenvue regardless of lawful difficulties and legal actions.
-
US pharma giant Eli Lilly to build factory in the Netherlands
Eli Lilly is spending USD 3bn in a brand-new manufacturing center in the Netherlands. The growth will certainly produce 500 brand-new work in the location.
